Evaluation of 22 neonatal gentamicin dosage protocols using a Bayesian approach

Paediatric and Perinatal Drug Therapy

Volumn 4, Issue 3, 2001, Pages 92-100

  Lannigan, Roisin ^a   Thomson, Alison ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Bayesian analysis; Dosage guidelines; Gentamicin; Neonates; Pharmacokinetics

Indexed keywords

GENTAMICIN;

ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; STEADY STATE;

EID: 0035746720     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pharmacodynamic factors of antibiotic efficacy
2. Aminoglycoside toxicity and relation to dose regimen
3. Aminoglycosides - 50 Years on
4. Population pharmacokinetics and pharmacodynamics: An underutilized resource
5. Evaluation of Bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less
6. The use of aminoglycosides in newborn infants
7. Population kinetics of gentamicin in neonates
8. Population pharmacokinetics of gentamicin in premature infants
9. Monitoring serum levels of gentamicin to develop a new regimen for gentamicin dosage in newborns
10. Pharmacokinetics of gentamicin in very low birth weight preterm infants
11. Incidence of potentially toxic concentrations of gentamicin in the neonate
12. Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates
13. An evaluation of gentamicin dosing according to renal function in neonates with suspected sepsis
14. Effectiveness of a gentamicin dosing protocol based on postconceptual age: Comparison to published neonatal guidelines
15. Prediction of gentamicin concentrations in neonates and infants using a Bayesian pharmacokinetic model
16. Population pharmacokinetics of gentamicin in neonates
17. New neonatal gentamicin dosing guidelines: Results of an evaluation of serum concentrations
18. Predictors of trough serum gentamicin concentrations in neonates
19. Estimation of gentamicin clearance and volume of distribution in neonates and young children
20. Population pharmacokinetics of gentamicin in neonates using a nonlinear mixed-effects model
21. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus
22. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation
23. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation
24. Once daily gentamicin dosing in neonates
25. Evaluation of an empirical dosing schedule for gentamicin in neonates
26. Optimal gentamicin dosing in neonates
27. Relationship of gentamicin serum concentrations to gestational age in preterm and term neonates
28. Gentamicin dosage intervals in neonates: Longer dosage interval - Less toxicity
29. The need for a loading dose of gentamicin in neonates
30. Prospective, randomized, controlled evaluation of a gentamicin loading dose in neonates
31. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring
32. Gentamicin dosage recommendations for neonates based on half-life predictions from birthweight
33. Tobramycin population pharmacokinetics in neonates
34. Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia
35. Experience in monitoring gentamicin therapy during treatment of serious Gram-negative sepsis
36. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
37. Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates